Capivasertib plus fulvestrant in HR-positive advanced breast cancer
AstraZeneca’s Capivasertib combined with fulvestrant reduces the risk of disease progression or death by 40%, compared with placebo plus fulvestrant, in patients with HR-positive advanced breast cancer, according to results from the Phase III ‘CAPItello-291’ study, presented at the 2022 San Antonio Symposium on Breast Cancer (SABCS). “Capivasertib represents a major advance in an area … Read more